More Patients and Medical Articles

Patients and Medical

How should pharma approach patient collaboration in the 2020s?

Lucy Fulford, (Apr 1, 2020)

Deeper, more holistic, strategic and ‘patient directed’ engagement will be a win for all this coming decade
Patients and Medical

Patients and RWE: Is this the year?

Tom Disley, (Mar 26, 2020)

There is reason to hope that the long-awaited breakthroughs flowing from patient-generated data are about to happen
Patients and Medical

Advancing through partnerships

Andrew Stone, (Mar 14, 2020)

Collaboration makes sense on many fronts on our journey to sustainably improve the lives of patients, says Merck’s Chris Round
Patients and Medical

Online hospitals – the journey from East to West

Katie Osborne, (Mar 13, 2020)

Artificial intelligence and digital are already transforming medical service delivery in China and it’s heading west rapidly
Patients and Medical

Building an innovation culture

Andrew Stone, (Mar 12, 2020)

Without the right approach to risk and culture, pharma may miss the big opportunities, says Bayer’s Sebastian Guth
Access and Evidence

Into pharma's roaring twenties

Paul Simms, (Jan 14, 2020)

A new decade is here. And despite the incredible science, pharma is ill-equipped.
Patients and Medical

Scaling patient engagement for deeper insights and better outcomes

Lucy Fulford, (Jan 13, 2020)

Scaling patient engagement offers a cascade of benefits if only pharma can gather the right insights
Patients and Medical

Pharma’s new ally: The caregiver

Andrew Stone, (Jan 12, 2020)

Pharma has only just started thinking about how engaging with caregivers could unlock a range of valuable insights
Patients and Medical

Patients united: Bringing the patient voice to genetics research

Nicola Davies, (Dec 5, 2019)

Parkinson’s disease genetic research has a powerful force to hand – an army of patients
Access and Evidence

Prescription drug pricing: The times they are a changin’

Ulrich Neumann, (Nov 25, 2019)

The political mood in the US on drug pricing at a national and state level is putting the pressure on pharma to demonstrate value